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ABSTRACT
Introduction: A study was performed to assess
the cost of a rapid molecular assay (PCR) for
diagnosis of Clostridium difficile infection (CDI)
and the impact of its routine use on patient
length of stay (LOS) in comparison with cell
culture cytotoxin neutralization assay (CCNA).
Methods: From March 2011 to September 2011,
Xpert C. difficile (Cepheid, Sunnyvale, CA,
USA) PCR was used on patients with suspicion
of CDI in two acute care hospitals in Abertawe
Bro Morgannwg University Health Board,
Swansea, Wales, UK. Test results were used for
patient management. LOS and time to
reportable result were compared for negative
and positive prospective patients tested by PCR
and historic control patients tested by CCNA
during March 2010 to September 2010. Tests
were priced using micro-costing and a cost
comparison analysis was undertaken.
Results: In total, 506 patients were included.
Time to reportable result for PCR samples was
1.53 h compared to 46.54 h for CCNA negatives
and 22.45 h for CCNA positives. Patients tested
by CCNA stayed 4.88 days longer in hospital
compared to PCR patients if they tested positive
and 7.03 days if tests were negative. The mean
reduction in LOS observed in our study has the
potential to generate cost savings of up to
£2,292.62 for every patient with suspected
CDI, if samples were to be tested routinely
with PCR instead of CCNA.
Conclusion: A rapid molecular test for C.
difficile in an acute hospital setting produced
quick results that led to a decrease in LOS
compared to historic CCNA control patients.
This could result in considerable savings
through reduced excess inpatient days.
Keywords: Cell culture cytotoxin
neutralization assay; Clostridium difficile;
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INTRODUCTION
Clostridium difficile is a fastidious anaerobe that
causes nosocomial antibiotic-associated colitis,
ranging from mild to severe disease, including
pseudo-membranous colitis and toxic
megacolon with a potentially fatal outcome
[1]. Even though the pathogenesis, diagnosis
and prevention of C. difficile infection (CDI)
have received particular attention in recent
years, CDI still remains a leading cause of
healthcare-associated diarrhea with a profound
clinical as well as economic impact [2].
Estimates of the financial burden of CDI have
been estimated to be between $2,454 and
$16,464 for every healthcare-acquired CDI case
in the US [3–5], £4,107 in the UK [6], and €7,147
in Germany [7]. The length of hospital stay
(LOS) has been identified as the main cost driver
in most economic studies of CDI [3, 4, 6], with
patients suffering from nosocomial CDI staying
on average between 3 and 26 days longer than
patients without CDI [6–9]. Furthermore, an
increase in LOS due to more severe disease was
observed in recent studies [10]. It has been
suggested that this may be partly attributable to
long turnaround times of assays and algorithms
used to detect the presence of C. difficile in stool
samples [11]. The cell culture cytotoxin
neutralization assay (CCNA) and also toxigenic
culture are historically considered to be the gold
standard assays for C. difficile detection [12, 13].
However, CCNA usually takes around 48 h until
results can be reported and it requires the ability
to perform cell culture [12]. Recent
developments in testing for CDI include
commercial and in-house polymerase chain
reaction (PCR), as well as glutamate
dehydrogenase (GDH) enzyme-based tests.
GDH assays require 4–6 h from receipt until
reportable results are available. GDH detects
toxigenic as well as non-toxigenic strains and
while it has been recommended as a screening
tool in combination with other confirmative
tests for GDH-positive samples [13, 14], its
sensitivity was reported to be less than optimal
[6, 15]. Although the performance of PCR assays
was found to exceed the clinical performance of
GDH-based individual tests and algorithms [15],
in-house molecular assays require technical
expertise and additional capital expenses.
Acquisition cost of commercially available kit-
based PCR assays are considered to be higher
compared to GDH or CCNA [16], but it has been
proposed that increased sensitivity of PCR could
ultimately lead to cost savings due to more
accurate diagnosis and reduced repeat testing
[15]. Faster turnaround time from testing to
reporting may result in shorter LOS and
decreased risk of transmission. The impact of
molecular methods for C. difficile detection on
duration of hospital stay compared to other
assays and potential cost savings due to shorter
hospital stays or fewer repeat samples has yet to
be determined.
In a prospective trial carried out in two acute
care hospitals in Swansea, UK, the clinical
utility of the real-time PCR test Xpert C.
difficile (Cepheid, Sunnyvale, CA, USA) was
assessed in comparison to CCNA. Xpert C.
difficile was found to be easy to use, rapid
(\1 h run time), clinically useful, sensitive,
and reliable in CDI diagnosis [17].
The aim of this cost comparison study was
to assess the cost of C. difficile PCR and its
impact on LOS for patients with suspicion of
CDI in an acute hospital site compared to
CCNA as the conventional diagnostic reference
method.
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METHODS
The cost comparison study was conducted in
parallel with a clinical study run at two acute
hospital sites within the Abertawe Bro
Morgannwg University Health Board
(ABMUHB) between March 2011 and
September 2011. This study investigated the
sensitivity and specificity of PCR, CCNA, GDH,
and a two-step GDH/toxin enzyme
immunoassay (EIA) algorithm with clinical
diagnosis as the Ref. [17]. Routinely collected
stool samples of patients with suspected CDI
were tested for the presence of C. difficile using
real-time PCR (GeneXpert testing platform;
Cepheid, Sunnyvale, CA, USA) and two-step
GDH/toxin EIA enzyme immunoassay
(Premier on a Dynex DS2 testing platform;
Dynex Technologies, Chantilly, VA, USA), in
addition to routine CCNA. The clinical study
[17] included patients[15 years with 2 or more
unformed stools (Bristol stool chart 5–7) within
a 24-h period who had been admitted to
hospital no shorter than 3 days before sample
collection to exclude community origin of
disease. PCR and CCNA results were reported
to the respective wards through the Laboratory
Information System as soon as they became
available. Once positives were identified,
patients were managed according to standard
clinical protocols for treatment of CDI [17]. All
positive PCR and/or CCNA results were
additionally phoned to the wards or infection
control nurses. Patients were immediately
isolated in a side room, if available, prior to
microbiological diagnosis, as per ABMUHB
policy.
The first 150 PCR-positive and 150 PCR-
negative patients of the clinical study were
planned to be included in the cost comparison
study. Separate from the ongoing clinical study,
as a control, patients with positive and negative
PCR samples were age and gender matched to
patients with positive or negative CCNA results
from the same calendar month in the previous
year. This led to the formation of four patient
groups comprising PCR-positive, PCR-negative,
CCNA-positive, and CCNA-negative patients.
Due to the fact that the clinical study focused
on diagnostic accuracy of various tests for C.
difficile detection in stool samples, GDH/toxin
EIA results were not reported to wards and not
used for patient management. It therefore had
to be excluded from the cost comparison study
as it would not have impacted on patient LOS.
Length of Hospital Stay
As main outcome, overall LOS from admission
to discharge, LOS from date of stool sample
(LOSSample) to discharge of positive and negative
intervention (i.e., PCR) and historic control
(i.e., CCNA) samples were compared. LOS data
were gathered using the Myrddin Patient
Administration System and the in-house
Laboratory Information System used routinely
at the two hospital sites and recorded
anonymously. Data were log-transformed
using SPSS 16.0 (IBM Corporation, Armonk,
NY, USA) to address skewness of data and
differences in duration of inpatient stay
between the groups were analyzed using one-
way analysis of variance (ANOVA). Average
hospital inpatient day costs were obtained
from National Health Service (NHS) reference
costs (2011) [18] and weighted for specialty and
activity.
Cost of Laboratory Testing
We collected costs in Pound (£) Sterling in 2011
adopting an NHS perspective. Cost of the
different tests was estimated using a micro-
costing bottom-up approach including data
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collection on resource use and costs of
materials, capital, waste, repeat samples,
overheads, staff time, and staff training time.
Resource use for each diagnostic test was
obtained by studying the standard operating
procedures and observing laboratory staff for a
day while they were performing the tasks
required for sample processing and evaluation.
Unit costs were applied according to
information from purchasing records, hospital
personnel records and statistics as well as
manufacturers and wholesalers. A yearly
workload of 10,000 samples was assumed for
costing calculations based on laboratory
statistics which showed that in 2011, 10,769
samples were tested using CCNA which was the
routine method in ABMUHB at that time. A
detailed break-down of all collected costs
including unit costs, resource use, calculations
and assumptions made und source of
information can be found in Appendix 1 in
the electronic supplementary material (ESM).
Cell Culture Cytotoxicity Neutralization
Assay (CCNA)
In Swansea, until April 2012, CCNA had been
the routine test for C. difficile in all diarrheal
specimens for over 30 years. The stool sample
was diluted 1:10 in phosphate buffered saline
(PBS), vortexed, and then centrifuged at
3,000 rpm for 20 min. A microtiter plate of
Vero cells in 2’ fetal calf maintenance medium
buffered with HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) was prepared.
Centrifuged PBS extracts of the feces were
added to the plate throughout the day using
two wells per sample, one of them containing
antitoxin neutralizing serum. Positive and
negative controls were set up on each plate,
incubated in CO2, at 36 C overnight,
examined under the microscope after 6–8 h
and again the next day (including Saturday)
and, if negative, read again after 48 h. On
weekends, new samples were not set up but
stored until Monday. The presence of C.
difficile toxin B was confirmed when at least
50% of the cells showed cytopathic effects in
the test well but not in the neutralized
antitoxin well.
Xpert C. difficile PCR Assay
Stool specimens were directly tested on the
closed GeneXpert random access platform,
allowing for an autonomous, fully integrated
and automated molecular analysis where
extraction, amplification, and identification
take place successively in the same cartridge.
The assay includes reagents for the detection of
C. difficile toxin B, binary toxin, and tcd
deletion nt117 as well as the sample
processing control. Any Xpert C. difficile assay
not yielding a result on the first attempt was
repeated using a new cartridge. If no result was
obtained upon retesting, the specimen was
reported as unresolved and excluded from the
study while patient management was decided
upon according to clinical diagnosis and the
routine CCNA result.
Cost Comparison
In order to assess potential cost savings or
additional costs to the health care service due
to the use of real-time PCR for detection of C.
difficile in stool samples, the number of C.
difficile samples per year tested in the ABMUHB,
number of repeat samples, ratio of positive to
negative samples, LOS for the four study
groups, and incremental testing costs were
considered. A detailed description of all
parameters included in the cost calculations
can be found in Appendix 2 in the ESM.
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Calculations were set up in Excel 2010
(Microsoft Corporation, Redmond, WA, USA)
based on the total number of 10,769 stool
samples tested in 2011 (laboratory statistics) in
ABMUHB and a rate of positive samples of
2.68% as 289 positive patients were recorded in
2011 [19]. The assumption was made that
initially positive patients were only tested
once, while initially negative patients were
tested twice if CCNA was used but only once
if PCR was used. Uncertainty within the data
was addressed by applying the 95% confidence
interval as the range for the LOS results and
material costs were reduced by 50% to account
for potential discounts given by manufacturers
or wholesalers. Additionally, the total number
of samples tested per year was adjusted from
10,000 to 15,000 and 5,000, respectively, to
investigate potential effects of economy of
scale on costs. The rate of C. difficile-positive
patients in ABMUHB in 2011 (6.39/1,000
admission [65 years) was below the all Wales
rate of 7.18 [19]. We therefore changed the
percentage of positive samples in our
calculations to account for different CDI rates
by doubling and halving the percentage of
positive tests. We also tested the impact of the
assumption that all initially CCNA-negative
patients would be retested once by applying
the assumption that no retesting was done for
any samples and increasing the number of
repeat tests to two. This prospective
interventional clinical study was approved by
the Public Health Wales Research &
Development committee. Ethical approval was
not deemed necessary as the specimens were
routinely requested according to ABMUHB
policy for clinical diagnosis, no additional
specimens were collected for study purposes
and the commercial diagnostic tests used in the
study received CE (Conformite´ Europe´enne)
marking for the diagnosis of CDI.
RESULTS
Five-hundred and twenty patients were
included in the study of which 14 had to be
excluded due to missing LOS data. While we
had planned to include the first 150 positive
patients, only 121 tested positive in the course
of the clinical study. Thus, data of 506 patients
were analyzed with 267 in the PCR group and
239 in the CCNA group. There were no
significant differences between groups for
patient age and gender. Mean age of patients
tested by PCR was 75.01 years with 50.6% male;
while mean age of CCNA tested control patients
was 74.84 years with 40.7% male participants.
Co-morbidities were similar across the groups.
The mean time until results could be reported to
the wards was 1.53 h for PCR, 22.45 h for
positive CCNA, and 46.54 h for negative
CCNA. Average time to results for GDH/toxin
EIA was 4.47 h. GDH results were not reported
to wards during the study, therefore no LOS
data could be linked to these results.
Based on micro-costing, testing cost per
sample was £36.18 for PCR, £7.53 for CCNA-
positive, and £8.78 for CCNA-negative samples
(Table 1). Staff hands-on time from sample
reception in the laboratory to reporting of the
results was more than five times more for CCNA
compared to PCR for negative samples and four
times more for positive samples (Table 1).
During the clinical study, 3.14% (33/1,051) of
samples tested by PCR did not yield a result at
the first attempt. Of these, 11 had to be
excluded from analysis due to insufficient
sample and 7 (all mucoid) samples produced
errors at second attempt. Cost of these repeat
samples was included in the overall PCR costing
(see Appendix 1 in the ESM). PCR-positive
patients were discharged on average 4.88 days
earlier than CCNA-positive patients based on
overall LOS and 4.33 days earlier when based on
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LOSSample PCR-negative patients were
discharged a mean 7.03 days earlier than
CCNA-negative patients considering overall
LOS and 6.86 days earlier when LOS was
calculated from date of sample collection
(Table 2). None of these differences were
statistically significant (P values 0.151–0.822).
Log-transformation of the skewed LOS data
(range 2–340 days) in order to meet the
assumption of normality and retesting with
ANOVA did not change the results.
Applying the mean values for LOS differences
in our calculations (Appendix 2 in the ESM),
routine use of real-time PCR had the potential to
save 38,247 bed days in ABMUHB in 2011 with
the main proportion of this figure (96%) being
contributed by shorter LOS of negative patients.
Mean cost savings of up to £2,292.62 per patient
could therefore be achieved by routinely using
PCR instead of CCNA (see Appendix 2 in the
ESM for description of calculations). In order to
investigate the robustness of the results, we
recalculated cost savings after changing the
values of key parameters (see Table 3). Since
the LOS results exhibited large variance and the
differences were not significant, potential cost
savings or additional investments were
calculated based on the 95% confidence
interval of the LOS results. Cost saving results
were found not to be robust when subject to
changes in duration of hospital stay of negative
patients. All other parameter changes did not
significantly alter the results (Table 3). Changes
in the quantity of samples processed per year did
not have a significant effect on cost savings even
though a small potential of economies of scale
based on capital investment and staff training
costs might be more significant for large
laboratories with high sample turnover
(Table 3). Due to the lack of statistical
significance and large range and variance in
LOS data, the results of this study cannot
definitely confirm that cost savings will be
made by using PCR. However, a clear trend can
be observed when results are tested for
robustness indicating a high potential for
savings (Table 3).
DISCUSSION
Fast and accurate laboratory results have been
suggested to impact patient management and
infection control measures [20]. The high
sensitivity and specificity of PCR-based assays
Table 1 Costs and resource utilization of PCR and CCNA testing for Clostridium difﬁcile infection per sample (based on
10,000 samples a year)
Resource PCR CCNA
Positive/negative Positive Negative
Material cost (including waste and repeat samples) (£) 34.59 2.08
Capital and overheads (£) 1.02 2.58
Staff cost (including training) (£) 0.57 2.87 4.11
Overall test cost (£) 36.18 7.53 8.78
Incremental cost of PCR compared to CCNA per test (£) n/a 28.65 27.40
Total hands-on staff time (sample reception to reporting) (min) 3.82 15.27 20.27
Average time to reportable result (sample reception to reporting) (h) 1.53 22.45 46.54
CCNA cell culture cytotoxin neutralization assay, n/a not applicable, PCR polymerase chain reaction
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for C. difficile detection and the rapid
turnaround time present a convincing
argument for the routine use of these
techniques, but the higher acquisition costs
per individual test still let laboratories
sometimes hesitate to adopt PCR in their CDI
testing routine [15, 16]. In our study, which
considered the impact of the testing assay on
duration of inpatient stay, Xpert C. difficile real-
time PCR was found to produce cost savings in
almost all scenarios investigated in comparison
to CCNA. Although differences in LOS were not
statistically significant in this study, a clear
trend is visible towards potentially large cost
savings when PCR-based methods are used for
C. difficile detection in comparison to CCNA.
This trend should be further confirmed by
future studies adequately powered to
overcome the large variance in LOS data. The
mean LOS for patients with suspicion of CDI
between 38 and 48 days found in this study is
higher compared to LOS reported in other
studies. Forster et al. [8] reported a median
LOS of 34 days, Vonberg et al. [7] found a
median LOS of 27 days, Song et al. [10] 22 days,
and Campbell et al. [9] stated a mean duration
between 21.0 and 29.3 days for patients
suffering from CDI acquired in hospital.
However, with the exception of Campbell
et al. [9], the mean age of patient populations
was considerably younger with 63.2 years [8],
55.9 years [7], and 57.6 years [10], compared to
75 years in our study, which may explain the
longer LOS due to potentially higher incidence
of co-morbidities.
The cost comparison discussed here only
considers the cost of diagnostic tests and the
change in duration of hospital stay observed in
this study. This approach appears valid
considering that cost of additional bed days
has been identified as the main cost driver in
CDI comprising up to 94% of the overall costs
[21, 22]. However, it may underestimate
potential additional cost savings due to cost
reductions in antibiotic treatment and isolation
days, as found by other studies [23, 24]. Rapid
PCR testing has also been suggested to have the
potential for cost savings for detection of
methicillin-resistant Staphylococcus aureus [25]
and sepsis [26] and to result in cost savings of
$1,037 per patient in infants with fever and
cerebrospinal fluid pleocytosis [27]. To our
knowledge, this study is the first to publish an
investigation of potential cost savings with a
Table 2 Length of hospital stay of inpatients suffering from diarrhea following PCR and CCNA testing for Clostridium
difﬁcile
Parameters CDI positive CDI negative
n (CCNA) 115 124
n (PCR) 121 146
LOS (CCNA) in days; mean (95% CI) 47.67 (37.85–57.48) 45.52 (37.99–53.05)
LOS (PCR) in days; mean (95% CI) 42.79 (35.95–49.63) 38.49 (32.05–44.92)






Number of patients in 2011 in ABMUHB 289 5,240
Inpatient days saved per year 1,410.32 36,837.20
ABMUHB Abertawe Bro Morgannwg University Health Board, CCNA cell culture cytotoxin neutralization assay, CDI
Clostridium difﬁcile infection, CI conﬁdence interval, LOS length of stay, PCR polymerase chain reaction
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PCR assay for diagnosing CDI compared to
CCNA.
The potential cost savings identified in our
study may be attributed to the faster
turnaround time of PCR-based screening tests
allowing for more efficient and accurate patient
management, which eventually results in
decreased average LOS of 4.88 days for CDI
positive and 7.03 for negative patients. Forster
et al. [8] suggested that calculating LOS
differences based on the overall LOS, not
treating C. difficile as a time-varying co-
variable, overestimates the effect of CDI on
duration of hospital stay as LOS before CDI will
be incorrectly attributed to C. difficile.
Differences in LOS and LOSSample for patients
tested by PCR compared to patients tested by
CCNA only differed by less than half a day in
our study, suggesting that the decreased LOS for
patients tested by PCR can primarily be
attributed to the impact of the diagnostic test.
GDH/toxin EIA-based assays also have shorter
turnaround times and test costs are lower when
compared to PCR. However, GDH and toxin
EIAs have repeatedly been reported to have a
lower sensitivity compared to PCR and CCNA
[11, 15, 28–30] despite being widely used and
recommended as a two-step algorithm [13, 14].
Our clinical study found that, when compared
to clinical diagnosis, 16.2% of true CDIs were
GDH negative and a further 59.7% of GDH
positive, clinically confirmed CDIs were
negative in toxin EIA [17]. This is in line with
Guerrero et al. [31] and Stahlmann et al. [32]
who reported that a third of CDI-positive
patients would have been missed using toxin
EIA compared to PCR. This is important, as
patients with EIA-negative results did not differ
in clinical presentation from EIA-positive
patients and posed a significant risk for
transmission [29]. Considering that around
25% of CDI patients were suggested to be
infected by ward-based patient-to-patient
transmission [33, 34], the clinical and financial
impact of misidentification of CDI cases would
be important. In laboratories using a two-step
GDH/toxin EIA algorithm, costs incurred due to
repeat testing performed when the GDH result
alone is positive, increased use of antibiotics for
those patients with GDH positives which do not
confirm with EIA and the increased length of
time to a positive toxin result have to be
considered. In our clinical study, 35.2% of
patients with GDH-positive specimens did not
clinically present CDI [17]. Retesting, treating
and isolating patients with false-positive results
wastes resources. We observed that GDH failed
to pick up a case of CDI, part of a ward outbreak,
which was presumptive C. difficile ribotype 027
positive with PCR and two GDH-positive 027
cases tested negative by toxin EIA.
The diagnostic accuracy of PCR methods has
been established in several trials [11, 15, 28, 29,
35]. However, additional positives identified by
PCR are often described as false positives when
results are only compared to other assays in the
laboratory setting and clinical presentation is
not considered [36]. Our clinical study showed
that out of 59 discrepant samples (CCNA
negative but PCR positive), 54 (91.5%) were
found to be true positives on clinical diagnosis
which demonstrates convincingly that PCR
results are reliable and accurate for diagnosing
CDI, at the same time reducing the need for
repeat testing. This was confirmed by Napierala
et al. [37] who found that after implementation
of PCR, testing volume as well as CDI rates
decreased significantly. Increased faith of
clinicians in a more accurate testing method
not only impacts on CDI-positive patients but
also affects CDI-negative patients, who can be
assessed for other gastrointestinal problems at an
earlier point in time without having to revisit
CDI as a cause for diarrhea. Other patients can be
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discharged without further C. difficile testing due
to the accurate negative results. This was
reflected in our study by an average earlier
discharge of 7.03 days for PCR-negative
patients when compared to matched CCNA
control patients. Similar results were reported
by Grein et al. [38] who found that average CDI
treatment days for negative patients and LOS
after CDI diagnosis were shorter with PCR testing
compared to toxin EIA and two-step testing.
GDH/toxin EIA results were not reported and
thus not used for patient management.
Therefore, no direct cost comparison of the
GDH followed by toxin EIA algorithm with
CCNA and PCR could be performed, which
might be considered a limitation of the study.
CCNA was used as a reference method as it was
the routine test for C. difficile detection in the
two hospitals at the time of data collection.
While it could be criticized that CCNA is not an
optimal reference due to its high turnaround
time and technical requirements, it has since
been shown to correlate well with clinical
diagnosis [39]. Our clinical study found a
sensitivity and specificity of 99.1% and 98.9%
for PCR and 51% and 99.4% for CCNA,
respectively, compared to clinical diagnosis
[17]. PCR testing produced 1 false negative
and 10 false positives in 1,034 patients
compared to CCNA which generated 55 false
negatives and 5 false positives. These
misidentifications will result in additional
resource use and cost due to unnecessary
treatment for false positives and repeat testing
and increased risk of transmission and spread of
infection for false negatives. Whereas repeat
testing due to false negative CCNA results was
accounted for in the calculations (Appendix 1
in the ESM), additional treatment costs were
not considered in this study which could
underestimate the cost saving potential of PCR
due to the high number of false negatives by
CCNA and the generally higher accuracy of PCR
testing [15]. Our study was conducted in two
acute hospitals in one trust in Wales and
calculations and results are based on figures
specific for ABMUHB. While this could limit
generalizability of the results, cost savings
generated by PCR testing were relatively
insensitive to changes in sample quantity, CDI
incidence and discount rates on material and
consumables required for testing and can
therefore be applied to various different
laboratory settings in the UK. Even though the
sample size of this study was large compared to
other studies on CDI, the lack of significance in
the LOS differences between the study groups is
a major limitation of this study which could be
addressed by future studies adequately powered
to overcome the large variances in patient LOS
observed in our study. Future research should
also take into account potential longer term
consequences such as CDI recurrences.
CONCLUSION
The routine use of a rapid molecular test for C.
difficile in an acute hospital setting produced
quick results that led to a decrease in LOS
compared to CCNA control patients. While
LOS differences were not statistically
significant in this study and costs of PCR
testing are higher than costs of CCNA per
sample, rapid molecular tests can realize
potentially large cost savings due to the
reduction of excess inpatient days and
reduction in cost per total patient care episode.
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